Asterias Biotherapeutics (AST) Stock Price, News & Analysis

Company Overview

Asterias Biotherapeutics (NYSEAMERICAN:AST) is a clinical‐stage biotechnology company focused on the development and commercialization of cell‐based therapies for serious diseases of the central nervous system, retina and other tissues. The company’s proprietary technology employs pluripotent stem cell–derived cell populations designed to replace or repair damaged cells and restore function in conditions that currently lack effective treatments.

The company’s lead candidate, AST-OPC1, comprises oligodendrocyte progenitor cells derived from human embryonic stem cells and is being evaluated for the treatment of spinal cord injury. In addition to its spinal cord program, Asterias has advanced immunotherapy candidates—AST-VAC1 and AST-VAC2—for central nervous system tumors and ovarian cancer, respectively, as well as an epithelial cell therapy (AST-AEC2) for acute tissue injury applications.

Founded in 2007 and headquartered in Fremont, California, Asterias BioTherapeutics licensed foundational stem cell technology from Geron Corporation in 2014. The company’s development efforts are supported by a management team with experience in regenerative medicine and cell therapy manufacturing. Asterias continues to pursue clinical trials in the United States and collaborates with academic and research institutions to advance its pipeline toward regulatory approval and commercialization.

Key Stats

• Today's Range: $0.0020 to $0.0020
• 50-Day Range: N/A
• 52-Week Range: $0.51 to $2.05
• Volume: 1,000 shs
• Average Volume: 136,653 shs
• Market Capitalization: $111.32 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 3/28/2017
• Today: 7/05/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NYSEAMERICAN:AST
• Previous Symbol: NYSEMKT:AST
• CIK: N/A
• Web: asteriasbiotherapeutics.com
• Phone: +1-510-4563805
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 55,659,000
• Free Float: N/A
• Market Cap: $111.32 thousand
• Optionable: Not Optionable
• Beta: N/A